Therapeutic targeting of SARS-CoV-2 using LNA-modified antisense oligonucleotides for the treatment of COVID-19 patients with acute respiratory disease
Related Posts
May 30, 2023 |
In its most recent newsletter, Alliance member organization Lasker Foundation speaks one-on-one with their 2022 Laureate James Rothman and shares […]
May 23, 2023 |
NEW HAVEN, CT – Yale University awarded an honorary Doctor of Science degree to Dr. France A. Córdova, president of […]